Navigation Links
Phase II Trial of Sanofi JAK2 Inhibitor in Myelofibrosis Met Primary Endpoint
Date:12/9/2012

those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, the Group's ability to benefit from external growth opportunities, trends in exchange rates and prevailing interest rates, the impact of cost containment policies and subsequent changes thereto, the average number of shares outstanding as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year ended December 31, 2011. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.


Contacts:  Sanofi  Media RelationsInvestor RelationsMarisol PeronSebastien MartelTel. : + (33) 1 53 77 45 02 

Tel. : + (33) 1 53 77 45 45E-mail: marisol.peron@sanofi.comE-mail: ir@sanofi.comLauren Musto  Oncology Division Communications Tel: 1 (617) 768-1993; Mobile 1 (781) 572-1147 E-mail: lauren.musto@sanofi.com Carrie Brown U.S. Oncology Division Communicatio
'/>"/>

SOURCE Sanofi
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
2. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
3. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
4. Retrospective Study Suggests that Stereotactic Ablative Radiotherapy (SABR) Can be a Viable Option for Treating Early-Stage Lung Cancer in Operable as well as Inoperable Patients; Phase III Randomized Trial Now Under Way
5. Ultragenyx Announces Phase 1 Results of UX001 in Hereditary Inclusion Body Myopathy (HIBM), a Rare Neuromuscular Disease
6. Lexicon Receives Funding for Phase 2 Clinical Trial of LX4211 in Type 1 Diabetes
7. Isis Initiates Phase 2 Study of ISIS-APOCIIIRx in Patients with Hypertriglyceridemia
8. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
9. Results Reported for Phase Ib Open-Label Clinical Trial for the Treatment of Depression Using External Trigeminal Nerve Stimulation (eTNS™) - The USB Port to the Brain™
10. Pearl Therapeutics Phase 2b Twice-Daily Dosing Data Suggest Morning and Evening Benefit of PT003 in Patients with COPD
11. Adamas Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA for Arimenda™
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)...  Early symptoms of diabetic eye and vision ... technology, coupled with yearly, comprehensive eye exams, are ... of eye diseases, including those associated with diabetes, ... untreated, these diseases can potentially lead to vision ... optometric researchers have deployed a new tool that ...
(Date:10/22/2014)... Oct. 22, 2014   Surefire Medical , Inc., ... designed to maximize targeted delivery of embolization agents in ... that oncologist John R. Daniels , MD of ... and surgical oncologist Steven C. Katz , MD ... Company,s Scientific Advisory Board (SAB).    "The ...
(Date:10/22/2014)... Oct. 22, 2014 WHEN: Wednesday, October 29, ... registration available at: http://bit.ly/1yStiU9 SPEAKERS: ... and Visionary Innovation Research Group Senior Research ... self-assembling materials, nanobots and flexible electronics are ... transform our lives in the coming decades. ...
Breaking Medicine Technology:Technology Advancements Enhance Early Detection of Eye Diseases Associated with Diabetes 2Technology Advancements Enhance Early Detection of Eye Diseases Associated with Diabetes 3Surefire Medical's Scientific Advisory Board Expands, Broadens Clinical Trial Expertise 2Futuristic Technologies That Will Transform Our World Beyond 2030 2Futuristic Technologies That Will Transform Our World Beyond 2030 3Futuristic Technologies That Will Transform Our World Beyond 2030 4
... Pfizer Inc. (NYSE: PFE ) today announced ... Read, 57, currently head of the Company,s global biopharmaceutical ... Read succeeds Jeffrey B. Kindler, who has retired from ... The Board,s Lead Independent Director, Constance J. Horner, said, ...
... Dec. 3, 2010 Opto Circuits (India) Ltd. [BSE ... completed the merger of its wholly-owned subsidiary, Jolt Acquisition ... result of the transaction, Cardiac Science has become a ... follows (i) Opto Circuits, acquisition, through a tender offer ...
Cached Medicine Technology:Pfizer Board of Directors Names Ian C. Read President and Chief Executive Officer 2Pfizer Board of Directors Names Ian C. Read President and Chief Executive Officer 3Pfizer Board of Directors Names Ian C. Read President and Chief Executive Officer 4Opto Circuits Successfully Completes Acquisition of Cardiac Science 2Opto Circuits Successfully Completes Acquisition of Cardiac Science 3
(Date:10/22/2014)... (PRWEB) October 22, 2014 Shriners Hospitals ... that will change the current location of Shriners Hospitals ... South Limestone across from the University of Kentucky Albert ... state-of-the-art ambulatory care center, owned and operated by Shriners ... orthopaedic needs of children and their families well into ...
(Date:10/22/2014)... Best Cheap Hosting USA is among ... site has recently announced that iPower ( http://www.best-cheap-hosting-usa.com/go/iPower/ ) ... from around the world. , “iPower is one of ... is providing various kinds of useful products for new ... offering excellent customer service and a number of features ...
(Date:10/22/2014)... Richard Carlson, Managing Partner of Blue ... over 25 years experience. Mr. Carlson is a ... related to EDI, B2B Commerce, RFID and Internet/Intranet technology. ... Board member for Pharmaceutical Commerce Magazine and a Gerson ... is a management and technology consulting firm focused solely ...
(Date:10/22/2014)... HealthDay Reporter , TUESDAY, Oct. 21, ... may lead to increased blood pressure, according to a new ... in blood pressure for young adult women or for teenagers, ... drank lightly or moderately, their risk of high blood pressure ... parallels studies in older adult men and women," said lead ...
(Date:10/20/2014)... October 20, 2014 The newly updated ... source of thousands of facts, figures and forecasts on ... 68 medical sector forecast categories the Worldwide Medical ... regional and national views on the worldwide medical market ... The report gives you data for 2010-2019, covering each ...
Breaking Medicine News(10 mins):Health News:Shriners Hospitals for Children - Lexington Announces Plan to Build New $47 Million Facility 2Health News:Shriners Hospitals for Children - Lexington Announces Plan to Build New $47 Million Facility 3Health News:Best Cheap Hosting USA Has Recently Announced The Best Cheap Web Hosting Companies In 2014 2Health News:Rich Carlson and Marc Duey to Hold Workshop at CBI’s Specialty Pharmacy and Distribution Networks Conference 2Health News:Binge Drinking May Boost Blood Pressure in Young Men 2Health News:Binge Drinking May Boost Blood Pressure in Young Men 3Health News:Binge Drinking May Boost Blood Pressure in Young Men 4Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 2Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 3Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 4
... pollution are two of the main causes of growing ... to conceive// normally. ,"Worldwide, one in ... percent of the infertility problems is contributed by the ... two key factors for childlessness among couples now," said ...
... government has signed a memorandum of understanding (MOU) with the ... supply of affordable//, high- quality drugs as well as diagnostics ... signed at the Presidential Villa with Nigerian President Olusegun Obasanjo ... visit to Nigeria, as witnesses. ,According to the ...
... issued by the Ministry of Health (MOH) says that ... test its Bird Flu Pandemic Readiness.// , ... including the MOH, the Ministry of Education, the Civil ... Maritime Port Authority, will participate in the exercise code-named ...
... Mayo Clinic study finds that after memory begins ... function to deteriorate in the progression from mild ... disease. ,Ron Petersen, M.D., Ph.D., Mayo ... function includes concentration, decision making, and higher-order problem ...
... The Federal Government and drug company, Roche are conducting talks ... ,According to Health Minister Tony Abbott discussions with ... to the Pharmaceutical Benefits Scheme (PBS). , Mr ... best possible deal for taxpayers as well as the best ...
... late for a person to start exercising for cutting down ... taking into consideration the people who were of the habit ... be of any strenuous nature but rather even simple measures ... epidemiologist at the University of Heidelberg in Germany said, "You ...
Cached Medicine News:Health News:Stress and Pollution are Major Cause of Infertility Among Urban Couples 2Health News:Decline in Concentration, Decision-Making and Problem-Solving 2Health News:Exercise Activities Helps To Avoid Heart Ailment 2
For the quantitative determination of Glycohemoglobin in blood....
The DSL-10-3000 ACTIVE Ferritin Enzyme-Linked Immunosorbent (ELISA) Kit provides materials for the quantitative measurement of ferritin in serum....
... Bio-Rad isotopic anemia assays ... minimal ,pipetting steps for ... about the processes ,involved ... the benefit to your ...
... ELISA test system is a qualitative screening assay ... sera. When performed according to the directional insert, ... ANAs commonly tested for, such as those against ... SSB, and Scl-70. The test is also capable ...
Medicine Products: